The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The activity of sonrotoclax plus dexamethasone in patients with R/R myeloma harboring t(11;14)
Abel Costa, MD, D’or Institute for Research and Education, São Paulo, Brazil, presents the results of a Phase Ib/II study (NCT04973605) evaluating the combination of sonrotoclax and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14). The study showed a promising overall response rate (ORR) of 75%, with over 50% of patients achieving a very good partial response (VGPR) or better. The combination exhibited a manageable safety profile with low rates of high-grade infections and toxicities. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
